{"prompt": "['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', 'A maximum of 114 participants at 3 sites, including RPCI, will be enrolled. Accrual is', 'Target Accrual and', 'Study Duration', 'expected to take up to 4 years. Each participant is expected to be on the study for two', 'years and will be followed according to NCCN guidelines.', 'Disease Evaluation: Baseline and as per the NCCN guidelines for T1/T2 SCC of the', 'head and neck.', 'Quality of Life Questionnaire: Baseline, post treatment at 12 - 16 weeks and 6, 12,', '18, and 24 months.', 'Hematology: Baseline.', 'Chemistry: Baseline.', 'Performance Status: Baseline, post treatment at 12 - 16 weeks, and at follow-up', 'visits.', 'Clinical Examination: Baseline and post treatment at 1 week, 4 - 6 weeks,', 'Study Procedures', '12 - 16 weeks. We will follow the subjects according to the NCCN guidelines for', 'patients with T1/T2 SCC, i.e. every 3 - 4 months (year 1), 3 - 6 months (year 2).', 'Vital Signs: Baseline, Day 0, post treatment at 1 week, 4 - 6 weeks, 12 - 16 weeks, and', 'at follow-up visits.', 'HPPH Infusion: Day 0', 'Blood Samples: Day 0, 7, and 4-6 weeks', 'Optical Spectroscopy: Day 1', 'Laser: Day 1', 'Adverse Events: From administration of study drug or surgery until 30 days after', 'receiving study drug or surgery.', 'The primary objective of this study is to test the non-inferiority of PDT to standard of', 'care by comparing the rate of tumor response after PDT to those obtained after surgery.', 'This is a randomized multicenter Phase II trial with PDT with HPPH for the treatment', 'of T1/T2 NO primary tumors of the oral cavity. The design is based on a test for non-', 'inferiority of PDT compared to standard of care with regards to tumor response.', 'Justification for use of a non-inferiority trial is that PDT may be viewed as a potential', 'replacement for standard of care if it is established as less toxic than the standard of', 'care yet still providing acceptable efficacy.', 'Sample Size Determination: The samples sizes of the trial are set at 57 in each of the', 'standard of care and PDT groups. With the proposed sample sizes, there is', 'approximately 80% power associated with the non-inferiority test when the true tumor', 'Statistical Analysis', 'response probabilities are equal to 85% in both groups.', 'Randomization: The randomization scheme will be generated at RPCI by the', 'biostatistician. 114 participants will be randomized at a ratio of 1:1 to be treated with', 'either standard of care surgery (57) or PDT with HPPH (57).', 'Efficacy Analysis: Objective tumor response will be tabulated overall. All participants', 'who randomized to PDT treatment or surgery will be evaluable for response. Tumor', 'response will be determined by comparing the photographs of the treated site (with', 'reference ruler) before and after PDT or surgery.', 'Safety Analysis: The frequency of toxicities will be tabulated by grade across all', 'cycles. All participants who randomized to HPPH PDT will be considered evaluable', 'for toxicity.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 4 of 64']['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', 'Participant Name (Network sites use participant initials):', 'Medical Record No. (Network sites use participant ID):', 'Title: A Randomized Multicenter Phase II Study Using 2-1|Hexyloxyethyl|-2-', 'Devinylpyropheophorbide-A (HPPH) with PDT versus Standard of Care Surgery', 'for Patients with T1/T2 NO Squamous Cell Carcinoma of the Oral Cavity', 'INCLUSION CRITERIA', 'Yes', 'No', 'N/A', 'All answers must be \"YES or \"N/A\" for participant enrollment.', 'Date', '1.', 'Age 18 years of age.', '2.', 'Have an ECOG Performance Status of < 2. Refer to Appendix D.', '3.', 'Participants with previously untreated T1/T2 NO squamous cell carcinoma', 'of the oral cavity with or without extension to the oropharynx.', '4.', 'Histologically confirmed squamous cell carcinoma of the target tumor(s)', '5.', 'Tumor thickness is 4 mm or less (measured clinically and/or by CT or', 'MRI scan).', '6.', 'CT or MRI of the neck to confirm staging.', '7.', 'Tumor accessible for unrestricted illumination for photodynamic therapy', '(PDT) (accessibility as determined by the physician).', '8.', 'Life expectancy of at least 12 months in the judgment of the physician.', '9.', 'Participants of child-bearing potential must agree to use adequate', 'contraceptive methods (e.g., hormonal or barrier method of birth control;', 'abstinence) prior to study entry and for the duration of study participation.', 'Should a woman become pregnant or suspect she is pregnant while she is', 'participating in this study, she should inform her treating physician', 'immediately.', '10. Participant or legal representative must understand the investigational nature', 'of this study and sign an Institutional Review Board approved written', 'informed consent form prior to receiving any study related procedure.', 'Study participant meets all entry criteria:', 'Yes', 'No', 'Investigator Signature:', 'Date:', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 5 of 64']\n\n###\n\n", "completion": "END"}